The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IMbrave151: A phase 2, randomized, double-blind, placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer.
 
Anthony B. El-Khoueiry
Honoraria - ABL bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; QED Therapeutics; Qurient; Roche/Genentech; Senti Biosciences; SERVIER; Tallac Therapeutics
Consulting or Advisory Role - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; QED Therapeutics; Qurient; Roche; Senti Biosciences; SERVIER; Tallac Therapeutics
Research Funding - Astex Pharmaceuticals; AstraZeneca; Fulgent Genetics
 
Zhenggang Ren
Consulting or Advisory Role - AstraZeneca; Merck Sharp & Dohme; Roche
 
Hongjae Chon
Consulting or Advisory Role - AstraZeneca; Bayer; BMS; Celgene Cancer Care Links/BMS; Eisai; Green Cross; Menarini; MSD Oncology; Ono Pharmaceutical; Roche; Sanofi; SERVIER; Sillajen
Speakers' Bureau - Bayer; BMS; Celgene/Bristol-Myers Squibb; Dong-A ST; Eisai; Menarini; Roche; Sanofi; SERVIER
Research Funding - Boryung (Inst); Dong-A ST (Inst); Roche (Inst)
 
Joon Oh Park
Consulting or Advisory Role - AstraZeneca; Celgene; MediRama; Merck Serono; SERVIER
Research Funding - ABL Bio; Celgene; Eutilex; medpacto; SERVIER
 
Jin Won Kim
Consulting or Advisory Role - AstraZeneca; BeiGene Beijing; BeiGene Beijing; BeyondBIO; Bristol-Myers Squibb/Celgene; Eisai; GC Cell; MSD; Ono Pharmaceutical; Roche; Sanofi; Servier; TCUBEit
 
Tiziana Pressiani
Consulting or Advisory Role - Bayer/Ipsen
Research Funding - AstraZeneca; Bayer; Lilly; Roche Pharma AG
Travel, Accommodations, Expenses - Roche
 
Daneng Li
Consulting or Advisory Role - Adagene; Delcath Systems; Eisai; Exelixis; Genentech; Ipsen; Merck; MINA THERAPEUTICS; QED Therapeutics; Tersera
Speakers' Bureau - Coherus Biosciences; Eisai; Exelixis; Ipsen; SERVIER; Tersera
Research Funding - AstraZeneca (Inst); Brooklyn ImmunoTherapeutics (Inst)
 
Lyudmila Zhukova
Honoraria - AstraZeneca; Lilly; Novartis
Consulting or Advisory Role - Novartis
 
Ming-Huang Chen
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Ono Pharmaceutical; Roche; TTY Biopharm
 
Stephen Paul Hack
Employment - Genentech/Roche
Stock and Other Ownership Interests - Roche
 
Stephanie Wu
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Bo Liu
Employment - Genentech/Roche
 
Yulei Wang
Employment - Genentech/Roche
 
Teresa Macarulla
Consulting or Advisory Role - Ability Pharma; Advance Medical; Amgen; Aptitude Health; AstraZeneca; Basilea; Baxter; BioLineRX; Celgene; Eisai; Ellipses Pharma; Esteve; Incyte; Ipsen; Janssen; Lilly; Medscape; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Paraxel; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Zymeworks
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER